2014“中國(南京)國際生物醫藥產業博覽會”將于5月14-16日在南京國際博覽中心舉行 。目前展會各項籌備工作進展良好,參展企業217家,其中包括來自美國、加拿大、瑞士、德國、法國、澳大利亞等13個國家和地區的海外參展企業36家。
“南京生物醫藥展”海外參展企業特別希望與以下具體領域的生命科學企業接洽:
生物技術或者生物制藥
醫療診斷
基因組學和生物信息學
再生性藥物、細胞療法
有意與下述企業進行現場洽談的人士,歡迎通過我們的網上預登記系統進行參觀預登記。http://www.biotechchina-nj.com/index.php?m=See&a=index
ANTEO DIAGNOSTICS 是一家用納米技術去改良固體表面(納米粒,納米磁珠,膠體金,滴定孔板等等)公司。公司擁有多項世界ZL的化學金屬聚合物技術,被稱為"Mix&Go"。Mix&Go的先進科技能快速把Mix&Go優良金屬聚合物結合到固體表面并且快速有效的結合蛋白質或核酸,使它應用于生物科技,醫療診斷和醫藥等行業。這種方法能使分析和生產更簡便并且降低成本。Mix&Go先進的科學技術能給生物科技帶來新的活力。
JRI是控制及監測系統領域的專家。
在設計和制造控制及監測系統領域,JRI擁有160年的經驗。
由JRI研發的監控系統模型可以控制各種類型的參數,例如溫度、濕度、壓力、水平,并且達到了法律規定的可塑性要求。
南京金斯瑞生物科技有限公司(原金思特科技(南京)有限公司)創建于2002年,伴隨著合成生物學的發展而高速成長,目前已成為世界上最大的基因合成供應商。公司總部位于美國新澤西州,在歐洲、日本和中國均設立了分公司。金斯瑞一直致力于為全世界的科研機構提供最好的研究服務。除了世界領先的基因合成服務,金斯瑞還提供與生物研究和新藥研發相關的技術服務,涵蓋生物試劑定制、藥物篩選建立和高通量篩選、抗體藥物研發、模式動物服務等。通過開發和應用創新的合成生物學技術,金斯瑞一直致力于幫助科研人員加速生物學領域的研究進展。
Meissner在全球范圍里設計,開發,生產,服務先進的高質量過濾器和流體處理系統。
Meissner先進的物料跟蹤和自動化生產操作提供了無以倫比的質量控制和可追溯性,保證了產品的最高性能和可靠性。
Meissner提供的過濾器和外殼、完整性測試儀、一次性使用生物儲液袋和液體輸送組件,其產品性能、質量、穩定性和成本效益都是最高水準的。
Meissner服務于制藥、生物技術、微電子技術、超純化學品、食品、飲料及有關行業。 從標準的和高容量的囊式過濾器及小流量組件,到濾芯、不銹鋼過濾器外殼和完整性測試儀,Meissner 的服務覆蓋了微濾應用的全部需求。
Meissner的One-Touch系列一次性使用的系統提供了前所未有的流體整體性應用和整體性的流體管理,滿足了流體運輸和存儲的需求。
全自動化的生產使Meissner過濾器在任何時候都具有最均勻的、一致的結構和性能。Meissner產品的組裝、測試和包裝都是在符合Class 7標準的潔凈工作室里完成。
Meissner技術服務機構(MTS)對Meissner的所有產品及其工業應用提供全面的技術支持。 MTS驗證服務為制藥行業客戶提供及時、全面的過濾器驗證服務。Meissner豐富的行業經驗,更容易驗證在制藥和生物技術應用的Meissner過濾器。MTS提供了全套完整的驗證服務,以備FDA或其他相關的監管機構進行審查。
世基生醫創立於2005年,獨家取得中央研究院全球專屬授權華法林(Warfarin)和其他藥物(如carbamazepine, Allopurinol 等)不良副作用的相關專利,進一步開發成檢測產品或診斷工具,並陸續獲得全球各國(包括中國、歐 、美、紐澳、印度、日本、東南亞等)完整技術專利證明。
世基生醫(pharmigene)的使命是開發專業基因診斷工具,提供民眾用藥前的用藥體質檢測,避免藥物不良副作用,以達到促進個人健康並推動個人化醫療的目標。
世基生醫在美國加州及臺灣均設有公司,並且在臺灣設有研發中心以及GMP/ISO分子檢測製造認證工廠
華聯生物科技(Phalanx Biotech Group)創立于2002年,總部位于新竹科學園區,并于美國舊金山灣區及中國昆山設立子公司;華聯為提供醫療器材制造商質量系統上的保證與國際認證的質量管理系統(QMS)標準,于2012年取得ISO 13485 / ISO 9001雙認證,提供完整高質量的產品與服務。
Life Sciences Advanced Technologies continues to build on the well-established biochemical product line we have manufactured and distributed since 1962. For almost fifty years, Life Sciences has been the world’s leading commercial producer of native AMV reverse transcriptase. Life Sciences has evolved into Life Sciences Advanced Technologies by building on its existing product line.
Life Sciences Advanced Technologies is committed to providing quality enzymes and biochemical products with an emphasis on service, value and customer satisfaction. We pride ourselves in striving to respond to your scientific needs with a sense of urgency and timeliness. Life Sciences has expanded our product line to meet the demands of the medical, scientific and research communities.
We are continuously collaborating with major pharmaceutical, biotechnology and research organizations to develop products that are impacting the global market. More specifically we have worked with companies, institutions, and individual research scientists to develop and improve products in PCR, enzyme modification, molecular diagnostic testing, immunology, and protein stability. Building on fifty years of scientific research experience, LSAT provides viable scientific knowledge to our clients and partners around the world.
BioAlps Association
BioAlps Association is the Life Sciences cluster from Western Switzerland. It is supported by the Cantons of Bern, Fribourg, Vaud, Neuchatel, Geneva, Valais, Jura and the Swiss State Secretariat for Economic Affairs.
With a mission of promoting the excellence and performance in MedTech and BioTech developments in this cluster at all levels: regionally, nationally and in the international arena. BioAlps is the entry point to a wealth of contacts, knowhow, knowledge and provides both personal and institutional support.
BioAlps organises events and co organises conventions, participates in a number of international events and supports conferences promoting the cluster and offering its members a wealth of networking opportunities.
BioAlps is the world most diversified life science cluster and one of the most dynamic. It comprises 780 companies, 20 academic institutions, 500 public and private laboratories, scientific parks, incubators bodies active in the life science representing 20'000 people and 5000 researchers.
BioAlps hosts during BIOTECH_2014 companies active in
- Therapeutics Products: oncology, immunology, infectious diseases,
rheumatology and ophthalmology
- Regenerative medicine: Autologous Platelet Rich Plasma
- 3D Bio Printing and Biomaterials
- Bio-Dashboard Web Services
- Bioactive surface coating and medical parts micro engraving device
- Swiss-China Innovation, Research, Technology and Education networking
,
GREATER GENEVA BERNE area (GGBa)
GREATER GENEVA BERNE area (GGBa) is an Economic Development Agency complementary to BioAlps ‘s mission offering tailored-made solutions to the Biotech and Medtech industries wishing to develop activities in Western Switzerland
provides expert insight into the region’s different cultural and economic strengths and all the information needed by an enterprise to be a success in Switzerland.
offers time-saving support to international companies
brings company ideas to the market by finding industrial partners and helping negotiation with them
provide free, tailor-made assistance in all stages of the process, from evaluating suitable locations to finalizing
identifies suitable premises close to potential industrial/technological partners in Biotech and Medtech sectors
provides investment opportunities for small and medium-sized enterprises (SME) and start-up businesses
establishes networking opportunities for biotech and medtech industries facilitating their integration
BiowebSpin
Bio Dashboard is the place to get information, exchange, work, and promote online worldwide in Life Sciences for researchers, executives, business developers, marketers, media, students, etc.
Beyond a social network, Biowebspin offers unique adapted tools to Pharma, Biotech, and Medtech professionals in order to optimize and simplify their daily tasks at work.
Engagement: Biowebspin helps associations, guilds, valorization organizations, and professionals or future professionals around the world who have the will to promote Biosciences and help its actors. Special offers or partnerships would be offered.
Debiopharm
Debiopharm International SA searches, evaluates and in-licenses promising drug candidates for development. Towards the end of the development process, the products are licensed out to pharmaceutical companies for world-wide marketing and sales.
The Company has successfully developed five products. These products include:
Eloxatin? for the treatment of colorectal cancer,
Decapeptyl?/Trelstar?/Pamorelin?/1-month, 3-month and 6-month formulations for the treatment of advanced prostate cancer, endometriosis, precocious puberty, in vitro fertilisation programmes, uterine fibroids, and
Moapar?/Salvacyl? for the treatment of severe sexual deviations.
Lyncée Tec
In life science applications, DHM-T1000 provides precise Quantitative Phase Measurements (QPM) of living cell cultures up to confluence, without the use of any contrast agent and with very low illumination power. It is very sensitive to small morphology modifications, and to intra-cellular concentration changes. The DHM-T1000 is thus an ideal instrument for high-throughput screening, time lapse measurements and time monitoring. Used in conjunction with the optional fluorescence module, it enables simultaneous DHM and fluorescence measurements.
Phasis
Bionano Gold coated glass slides: Gold thin films grown on microscope glass slides with Titanium adhesion layer.
Au(111) thin films on mica: Gold (111) epitaxial thin films grown on freshly cleaved mica substrates
R&D within PHASIS: PHASIS is involved in several applied research projects with both academic and industrial partners. PHASIS is interested in the use of new materials to bring new insights in the field of gas sensors. Moreover, the flexibility of PHASIS' equipment allows the production of thin films with tailored properties.
regenHU
3D Bio-Printers:
3D cellular constructs on-demand Bottom-up fabrication of scaffolds-cell-constructs requires scaffold materials that can be controlled with regards to their microarchitecture but also chemical and physical properties. A Bio-printer with high resolution permits the spatial control of scaffold materials and also enables the deposition of cells in target areas.
Bio-Manufacturing:
Usage of smart biomaterials such as cellular components shows high promises to enter a new dimension to address actual unmet medical needs
BioInk:
Universal Matrix for 3D Tissue Printing. The BioInkTM is a semi-synthetic hydrogel supporting cell growth of different cell types (fibroblasts, keratinocytes, etc.) by providing cell adhesion sites and mimicking the natural extracellular matrix. The BioInkTM is provided as a ready-to-use device to print 3D tissues. Critical parameters such as matrix stiffness, cell adhesion can be tailored. Exclusively designed for BioFactory? and 3DDiscovery? tissue printers.
Fluid dispenser:
The ALL-IN-ONE Drug discovery liquid handling device. The 3DDiscovery? instrument is a multi-functional liquid handling device responding to today's requirements of 2D/3D Drug Discovery/Toxicology screening applications. The 3DDiscovery? instrument is both a powerful FLUID DISPENSER addressing today's industrial needs, as well as a three-dimensional BIOPRINTER responding to the upcoming challenges facing the pharmaceutical, biotech and clinical research organizations.
,
Regen Lab
Application of Autologous Platelet Rich Plasma has been evaluated in various medical disciplines including orthopaedics, sports medicine, wound healing, neurosurgery, dentistry, ophthalmology as well as cosmetic, plastic, maxillofacial and cardiothoracic surgery.
The technology is processing the patient′s own blood, fat or bone marrow to use the concentrated cells.
Autologous Platelet Rich Plasma also contains fibrin, fibronectin and vitronectin that act as cell adhesion molecules for osteoconduction and as a matrix for bone, connective tissue and epithelial migration 4.
The Regen Extracell BMC technology and its products aim is to dramatically enhance tissue regeneration toward a quicker and more successful patient’s recovery. At the edge of the latest developments of the cellular therapy research, the Regen Extracell contribution in the world of orthopaedics wishes to be safe and realistic
Swissnex - China
Swissnex is a network with nodes in the world's most innovative hubs, where the future is being shaped. We take an active role in strengthening Switzerland's leadership as a world-class location for science, education and innovation. Our core value lies in our ability to:
Strengthen Switzerland's profile as a nation of leading-edge research, quality, innovation and openness
Connect scientists, researchers, entrepreneurs, policy-makers and thought leaders with inspiring peers and new ideas on either side of the globe
Facilitate academic programs, global innovation strategies, and knowledge exchange
Create and present transdisciplinary projects in imaginative ways
Network with relevant contacts at universities, research institutions, and companies to maintain a powerful web of worldwide knowledge
Support internationalization efforts of Swiss academic institutions
Share innovative achievements and emerging trends in the host country and in Switzerland
Inform on developments in science, technology, education and innovation process
Participate in our communities and interact with Swiss and local partners to bring added value
TRB Chemedica
The company markets a range of ethical pharmaceuticals and medical devices in more than 40 countries. They have a subsidiary in Hong Kong and are committed to growth in the international arena
Development of its own products in niche therapeutic areas (rheumatology, ophthalmology and neurology):
- Diacerein: the first and only oral IL-1 inhibitor for use in the treatment of osteoarthritis,
- Hyaluronic Acid: for intra-articular administration in the treatment of osteoarthritis,
- Vislube and Vismed lines: for topical ocular use as lubricants in the treatment of sensations of ocular dryness,
- Visiol: for intra-ocular use during ocular surgery.
- Drug for the treatment of Parkinson disease.
Springer and Adis products
Springer is a leading global publisher and publishes around 2000 journals and more than 4000 new books yearly. The Adis journals and newsletters and the three Adis databases are part of the Springer collection: Adis R&D Insight, Adis Clinical Trials Insight and Pharmacovigilance Insight.
With Springer for Research and Development Content Solutions, companies of all sizes can purchase and deliver Springer products tailored for their employee’s specific needs. Customizable purchase models and flexible pricing enable companies to select only the content that they require.
For instant access, reference materials, proven fixes and best practices, trusted, targeted information: rd.springer.com
點擊這里進行在線參觀預登記!
聯系方式
電話:025-83418350
傳真:025-83518322-818
郵箱:info@biotechchina-nj.com
地址:南京市長江路188號德基大廈12樓B座
未來生物醫藥產業的發展方向受技術突破難度和產業發展前景等因素影響,具有巨大的不確定性。最近,西湖大學未來產業研究中心挖掘出對全球生物醫藥產業發展方向將可能產生重大影響的30項關鍵技術。西湖大學校長施一......
“初步形成‘新藥篩選—動物實驗—臨床研究—注冊上市’鏈條,初步形成一批典型兩業融合發展模式。”這是試點兩年,位于北京市大興區的生物醫藥產業基地交出的兩業融合成績單。推動先進制造業與現代服務業融合是增強......
·“不同的學校、不同的學院有不同的培養特色和使命,不僅僅要集中于頭部的創新,也要更多關注產業端的人才,這樣才能使生物醫藥的產業鏈更加完整。”·“大多數高校的規定是,在一定的期限內如果沒有做出一定的成果......
中國深圳–2023年5月30日–近日,2023年國家標準宣貫培訓暨生物實驗室自動化技術標準化交流研討會在深圳舉辦,健康科學領先企業Revvity與相關領域專家、學者、企業代表等百余位嘉賓共同參與此次研......
5月22日,在2023大灣區科學論壇生物醫藥與健康分論壇上,中國工程院院士鐘南山透露,能覆蓋XBB變異株的疫苗有2個已經初步被批準,很快能面世。近日,世界衛生組織(WHO)咨詢小組對今年的新冠疫苗加強......
美國藥典委員會(USP)于2023年5月1日在藥典論壇PF49(3)中發布了一篇提議新通則:通則<1132.1>質譜法測定生物藥中殘留宿主細胞蛋白(ResidualHostCellProt......
2023年5月,巨匠生物完成了數千萬人民幣的A輪融資,本輪融資由中信資本旗下中信創投獨家投資。所募集資金將主要用于研發實驗室和高級別生產車間建設、核心技術團隊及管理人員招募、全國性的營銷團隊組建,以提......
自從科創板向未盈利公司敞開大門之后,零營收的企業紛紛醞釀IPO,這其中就包含了不少生物醫藥企業。今年以來,零營收的藥企擬IPO隊伍明顯擴容,但并非所有企業都能如愿順利上岸。不久前,備受業界關注的零營收......
近日,上海市生物醫藥行業協會認證的“上海市生物技術高技能人才培養實訓基地”在探實生物正式掛牌成立。為了解決爆發增長的生物醫藥產業帶來的大量專業技術人才缺口,探實生物與上海市生物醫藥行業協會合作,利用已......
2月28日,由河北省科學技術廳、德國聯邦經濟發展和對外貿易聯合總會主辦的中德生物醫藥產業對接會在石家莊和柏林通過“線下+線上”方式舉行。省科技廳、德國勃蘭登堡州、石家莊高新區管委會、中國醫藥保健品進出......